CMEOF (Creo Medical Group) LT-Debt-to-Total-Asset: 0.03 (As of Dec. 2025)

What is Creo Medical Group LT-Debt-to-Total-Asset?

Creo Medical Group CMEOF 52 LT-Debt-to-Total-Asset is 0.03 as of Dec. 2025. GuruFocus rates CMEOF with a GF Score™ of 52/100 and a GF Value™ of $0.25. The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Creo Medical Group's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.03.

Creo Medical Group's long-term debt to total assets ratio declined from Dec. 2024 (0.03) to Dec. 2025 (0.03). It may suggest that Creo Medical Group is progressively becoming less dependent on debt to grow their business.

Creo Medical Group (OTCPK:CMEOF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Creo Medical Group LT-Debt-to-Total-Asset Related Terms

Creo Medical Group LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Creo Medical Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creo Medical Group LT-Debt-to-Total-Asset Chart

Creo Medical Group Annual Data

Trend

Feb15

Feb16

Jun17

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.08

0.07

0.03

Creo Medical Group Semi-Annual Data
	Feb15	Feb16	Dec16	Jun17	Dec17	Jun18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.07	0.15	0.03	0.03	0.03

52GF Score

Creo Medical Group PLC CMEOF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Creo Medical Group LT-Debt-to-Total-Asset Calculation

Creo Medical Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	2.41	/	79.116
	=	0.03

Creo Medical Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	2.41	/	79.116
	=	0.03

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.03 mean?

Creo Medical Group (CMEOF) has a LT-Debt-to-Total-Asset of 0.03 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Creo Medical Group and its competitors.

Is Creo Medical Group's LT-Debt-to-Total-Asset too high?

Creo Medical Group's current LT-Debt-to-Total-Asset is 0.03. Overall, Creo Medical Group has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.

How does Creo Medical Group's LT-Debt-to-Total-Asset compare to ABT and SYK?

Creo Medical Group's LT-Debt-to-Total-Asset of 0.03 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Creo Medical Group and its competitors. Creo Medical Group's current LT-Debt-to-Total-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Creo Medical Group stock overvalued right now?

Creo Medical Group (CMEOF) has a current LT-Debt-to-Total-Asset of 0.03. The stock's GF Value™ is $0.25, compared to a current price of $0.20 — trading 20% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.03. Creo Medical Group's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current LT-Debt-to-Total-Asset is 0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creo Medical Group (CMEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.

Key valuation signals for CMEOF:

LT-Debt-to-Total-Asset: 0.03
GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creo Medical Group Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies LSE:AOTI LSE:IHC LSE:EKF LSE:SUN LSE:NIOX ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760 STE ZBH XSWX:SOON LSE:SN.PEN

Other Exchanges CREO:UK

Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH

Website https://www.creomedical.com

Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.

52GF Score

Get the complete analysis for CMEOF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20

Price

$0.25

GF Value

View CMEOF Analysis

See LT-Debt-to-Total-Asset data for all stocks →